In TME, the anti-cancer immune response is mediated primarily by CD8+ T cells, which are controlled by co-inhibitory signaling molecules, including programmed cell death protein 1 ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4). The gene discussed is CD8A; the disease is cancer.